Attovia Therapeutics, Inc.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
Attovia Therapeutics, Inc. is publicly traded on NASDAQ under the ticker ATTO.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Can you invest in Attovia Therapeutics, Inc.?
Yes. Attovia Therapeutics, Inc. is publicly traded on NASDAQ under the ticker ATTO.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Attovia Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.